I've told the story several times. But at the risk of being repetitive, I'll tell it again...

Back in the 1999 to 2000, I was listening to an investor conference call in which Merck's (NYSE:MRK) chief executive, Raymond Gilmartin was speaking.

After running through a litany of reasons why he thought that Merck was well-positioned to grow in the future, an analyst asked whether the company was planning to merge, combine or otherwise acquire another large drug maker.

The question was particularly relevant as a number of high-profile pharmaceutical firms had recently combined forces or were planning large-scale combinations.

Gilmartin nixed the idea right off the bat, essentially saying (and this is my interpretation of his response) that Merck didn't need to combine forces because the company was No. 1.

Perhaps not surprisingly, Gilmartin ended up eating a big slice of humble pie as Merck's drug pipeline languished, and its earnings paled in comparison to those at some of the other big pharmas.

What i found really disturbing about the whole event was that by so readily dismissing the idea of combining forces with another big player, Gilmartin essentially took a potential stock-driving (or supporting) catalyst right off the table. Soon after those comments were made Merck's stock was relegated to the doghouse - between 2001 and 2005 the company saw its stock price almost cut in half.

Merck Hasn't Learned
Earlier this week, I was perusing the news and I came across an article in which Merck's president for Europe, the Middle East, Africa and Canada, Stefan Oschmann, said that he thought that the U.S. drug maker might be interested in bulking up its pipeline by purchasing biotech firms - particularly those with late-stage drugs in the hopper. This seemed good.

However, in conjunction with these comments he also indicated that a large-scale mega merger probably wasn't in the cards. Specifically Oschmann said, "Mega mergers have in most cases not delivered what they had promised ... We don't necessarily think that a mega merger is the right thing."

I just don't get it. The company has the obligation to tell the truth, particularly to its shareholders. However, to taking that potential catalyst off the table again is just a questionable move.

Merck's stock has made a nice comeback over the last year, and is now pretty valuable currency. Plus Merck's reputation seems to be on the mend. You'd think that it would want to keep the momentum going by aggressively scooping up smaller companies or keeping its options open and at least kicking the tires of possible pharma targets?

The Bottom Line
As I mentioned in my last piece on MRK, I think the shares are a 'buy', and I still stick by that. (To read the entire article, see Two Big Names With Big Upside (PG, MRK) .)

However, I am really put off by Oschmann's comments. Going forward, I hope that management learns to keep its options open, and to remember that a few simple words can have a big impact on the share price.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Options & Futures

    Use Options to Hedge Against Iron Ore Downslide

    Using iron ore options is a way to take advantage of a current downslide in iron ore prices, whether for producers or traders.
  2. Home & Auto

    Understanding Rent-to-Own Contracts

    They can work for you or against you. Here's how to negotiate a fair one.
  3. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  4. Home & Auto

    Avoiding the 5 Most Common Rent-to-Own Mistakes

    Pitfalls that a prospective tenant-buyer could encounter on the road to purchase – and how not to stumble into them.
  5. Home & Auto

    Renting vs. Owning: Which is Better for You?

    Despite the conventional wisdom, renting might make more financial sense than you think.
  6. Investing Basics

    Explaining Options Contracts

    Options contracts grant the owner the right to buy or sell shares of a security in the future at a given price.
  7. Home & Auto

    When Are Rent-to-Own Homes a Good Idea?

    Lease now and pay later can work – for a select few.
  8. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  9. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  10. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  1. Implied Volatility - IV

    The estimated volatility of a security's price.
  2. Plain Vanilla

    The most basic or standard version of a financial instrument, ...
  3. Normal Profit

    An economic condition occurring when the difference between a ...
  4. Theta

    A measure of the rate of decline in the value of an option due ...
  5. Equity

    The value of an asset less the value of all liabilities on that ...
  6. Derivative

    A security with a price that is dependent upon or derived from ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. How does a forward contract differ from a call option?

    Forward contracts and call options are different financial instruments that allow two parties to purchase or sell assets ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!